Rongyi Chen
Overview
Explore the profile of Rongyi Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
521
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu D, Fan S, Huang X, Gu W, Yin Y, Zhang Z, et al.
Health Care Sci
. 2024 Dec;
3(6):475-492.
PMID: 39735279
Introduction: This study protocol specifies the primary research line and theoretical framework of the 2023 Survey of the Psychology and Behavior of the Chinese Population. It aims to establish a...
2.
Ma L, Sun Y, Liu Y, Huang H, Chen R, Li C, et al.
Clin Exp Rheumatol
. 2024 Oct;
PMID: 39360375
Objectives: The role of ultrasonography for evaluating vessel wall inflammation in Takayasu's arteritis (TAK) is well-recognised; however, an effective approach for the quantitative assessment of disease activity remains lacking. This...
3.
Li S, Li K, Li S, Zou J, Zhan J, Li J, et al.
Oral Oncol
. 2024 Jul;
157:106949.
PMID: 39013228
No abstract available.
4.
Wang J, Sun Y, Chen R, Meng D, Wei Y, Jiang L, et al.
J Autoimmun
. 2024 Jul;
148:103277.
PMID: 38972101
Background: Vascular fibrosis directly causes vascular thickening in Takayasu arteritis (TAK), in which sustained transforming growth factor beta (TGF-β) activation is critical. Understanding TGF-β activation regulation and blocking it might...
5.
Fu Z, Zhang L, Chen R, Zhan J, Zhong J, Zheng W, et al.
Cancer Lett
. 2024 Jul;
598:217099.
PMID: 38971491
An optimum safety excision margin (EM) delineated by precise demarcation of field cancerization along with reliable biomarkers that enable predicting and timely evaluating patients' response to immunotherapy significantly impact effective...
6.
Yang L, Zhang X, Chen W, Sena A, Zheng H, Jiang Y, et al.
J Infect Dis
. 2024 Jun;
230(6):e1322-e1333.
PMID: 38884588
Background: The global resurgence of syphilis necessitates vaccine development. Methods: We collected ulcer exudates and blood from 17 participants with primary syphilis (PS) and skin biopsies and blood from 51...
7.
Xiong X, Chen R, Wang L, Huang N, Huang L, Wang C, et al.
JAAD Case Rep
. 2024 Apr;
46:85-88.
PMID: 38577497
No abstract available.
8.
Cai L, Jiang C, Zhang G, Fang H, Wang J, Li Y, et al.
Br J Dermatol
. 2024 Feb;
191(3):336-343.
PMID: 38366639
Background: Xeligekimab (GR1501) is a fully human monoclonal antibody that selectively neutralizes interleukin (IL)-17A and has shown potential efficacy in treating moderate-to-severe psoriasis in preliminary trials. Objectives: To evaluate the...
9.
Li S, Luo S, Wei N, Lin A, Wang D, Lin P, et al.
Oral Oncol
. 2023 Nov;
147:106602.
PMID: 37944219
No abstract available.
10.
Yang L, Zhang X, Chen W, Sena A, Zheng H, Jiang Y, et al.
medRxiv
. 2023 Oct;
PMID: 37905017
Background: The global resurgence of syphilis requires novel prevention strategies. Whole genome sequencing (WGS) of ( ) using different specimen types is essential for vaccine development. Methods: Patients with primary...